Ratings EC Healthcare

Equities

2138

KYG3037S1021

Market Closed - Hong Kong S.E. 04:08:25 2024-05-27 am EDT 5-day change 1st Jan Change
1.66 HKD +0.61% Intraday chart for EC Healthcare -10.27% -4.60%

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 48% by 2026.
  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The company appears to be poorly valued given its net asset value.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The opinion of analysts covering the stock has improved over the past four months.

Weaknesses

  • The company does not generate enough profits, which is an alarming weak point.
  • The company benefits from high valuations in earnings multiples.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Sector: Personal Services

1st Jan change Capi. Investor Rating ESG Refinitiv
-4.60% 250M -
-20.68% 524M
D+
+35.74% 451M -
-6.90% 254M -
-24.67% 94.88M -
-4.92% 83.53M -
-2.58% 81.17M -
-20.69% 58.88M - -
-13.75% 53.31M - -
-44.44% 52.89M - -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes